← Back to Clinical Trials
Recruiting NCT06810661

NCT06810661 Managing Frailty Through Mobilization in Males and Female Inpatients With Cardiovascular Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06810661
Status Recruiting
Phase
Sponsor Université de Sherbrooke
Condition Cardiovascular Diseases
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-01-06
Primary Completion 2026-08-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Mobility promotion

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-01-06 with a primary completion date of 2026-08-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Frailty describes the overall health of a person. Inpatients with cardiovascular problems have a higher risk for frailty - or the sick are more likely to get sicker - causing longer hospital stays, hospital readmission, and death. Females are particularly vulnerable to these problems, generally displaying higher frailty levels than males. In hospital, patients spend almost all their time in bed, and this lack of movement worsens cardiovascular and musculoskeletal health, sometimes lengthening patients' hospital stay and priming them for another cardiovascular event. Prolonged sedentary time may be more detrimental on frailty among females than males. The proposed pilot project will test if an in-hospital General Medicine mobilization program reduces frailty (measure of overall health) in male and female inpatients with cardiovascular disease. A Kinesiologist will provide daily check-ins and promote daily movement (e.g., standing more, resistance bands, physical activity promotion, etc.). The investigators expect both males and females will lower their frailty levels, but given their higher frailty levels in general and because females are typically less active than males, the investigators expect the intervention's effects to be greatest among females. Sixty patients (30 females) will be recruited. Patients with a major heart problem, projected to be in-hospital for at least 3-days, and can independently provide consent. Frailty will be measured using a validated questionnaire. Participants will also be equipped with activity monitors for 24h/d continuous wear to measure amount of time spent stepping, sitting, and lying. Hospital records will be used for length of stay and readmissions. The investigators will compare the outcomes (activity and frailty) between males and females to determine if the intervention impacted each sex differently. This work will guide improved care plans to decrease frailty and improve health outcomes in both male and female patients with heart problems.

Eligibility Criteria

Inclusion Criteria: * Patients who are admitted to unit 4C at the Vitalité Health Network * Patients who have a cardiovascular disease (e.g., heart failure) * Those who are projected to be in-hospital for at least 3-days * Patients who are not in a shared room with another study participant * Patients who are able to independently provide consent or have a caregiver provide consent * Can communication in French or English Exclusion Criteria: -Patients enrolled in other clinical trials or interventions that might confound the results of the study.

Contact & Investigator

Central Contact

Myles W O'Brien, PhD

✉ Myles.OBrien@USherbrooke.ca

📞 (506) 863-2250

Frequently Asked Questions

Who can join the NCT06810661 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06810661 currently recruiting?

Yes, NCT06810661 is actively recruiting participants. Contact the research team at Myles.OBrien@USherbrooke.ca for enrollment information.

Where is the NCT06810661 trial being conducted?

This trial is being conducted at Moncton, Canada.

Who is sponsoring the NCT06810661 clinical trial?

NCT06810661 is sponsored by Université de Sherbrooke. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology